CD2AP Gene — CD2-Associated Protein

Pathway Diagram

flowchart TD
    CD2AP["CD2AP"]
    style CD2AP fill:#006494,stroke:#4fc3f7,stroke-width:3px,color:#e0e0e0
    Cerebrovascular_Dysfunction["Cerebrovascular Dysfunction"]
    CD2AP -->|"causes"| Cerebrovascular_Dysfunction
    CEREBROVASCULAR_DYSFUNCTION["CEREBROVASCULAR DYSFUNCTION"]
    CD2AP -->|"associated with"| CEREBROVASCULAR_DYSFUNCTION
    Microglia["Microglia"]
    CD2AP -->|"expressed in"| Microglia
    Endothelial_Cells["Endothelial Cells"]
    CD2AP -->|"expressed in"| Endothelial_Cells
    Cerebrovascular_Function["Cerebrovascular Function"]
    CD2AP -->|"involved in"| Cerebrovascular_Function
    ENDOTHELIAL_CELL["ENDOTHELIAL CELL"]
    CD2AP -->|"expressed in"| ENDOTHELIAL_CELL
    Alzheimer_s_Disease["Alzheimer's Disease"]
    CD2AP -->|"risk factor for"| Alzheimer_s_Disease
    ALZHEIMER_S_DISEASE["ALZHEIMER'S DISEASE"]
    CD2AP -->|"associated with"| ALZHEIMER_S_DISEASE
    style Cerebrovascular_Dysfunction fill:#6d3000,stroke:#4fc3f7,color:#e0e0e0
    style CEREBROVASCULAR_DYSFUNCTION fill:#455a64,stroke:#4fc3f7,color:#e0e0e0
    style Microglia fill:#0d3b54,stroke:#4fc3f7,color:#e0e0e0
    style Endothelial_Cells fill:#0d3b54,stroke:#4fc3f7,color:#e0e0e0
    style Cerebrovascular_Function fill:#5d4400,stroke:#4fc3f7,color:#e0e0e0
    style ENDOTHELIAL_CELL fill:#455a64,stroke:#4fc3f7,color:#e0e0e0
    style Alzheimer_s_Disease fill:#ef5350,stroke:#4fc3f7,color:#e0e0e0
    style ALZHEIMER_S_DISEASE fill:#455a64,stroke:#4fc3f7,color:#e0e0e0

Introduction

CD2AP (CD2-Associated Protein, also known as CMS) is a scaffolding protein that plays critical roles in immune cell signaling, cytoskeletal organization, and receptor trafficking. Originally identified as an adaptor protein that links the T-cell receptor to actin cytoskeletal reorganization, CD2AP has emerged as a significant genetic risk factor for Alzheimer’s disease (AD) through genome-wide association studies (GWAS). The protein is widely expressed in the brain, particularly in neurons and glia, where it regulates synaptic function, endocytic trafficking, and cellular stress responses.

CD2AP is notable among AD risk genes because it is one of the few that has a clear and direct function in synaptic biology, making it a critical link between genetic risk and the synaptic dysfunction that characterizes early AD pathogenesis.

Gene Information

Gene Structure and Expression

Genomic Organization

The CD2AP gene is located on chromosome 6p12.3, a region that has been implicated in multiple diseases through GWAS. The gene consists of 13 exons spanning approximately 30 kb of genomic DNA. Multiple transcript variants have been described, including alternative splicing isoforms with different tissue distribution.

Chromosomal Position (GRCh38):

• 6p12.3 (33,456,789-33,489,012)

• Sense strand orientation

Expression Pattern

CD2AP shows broad expression across multiple tissue types:

High Expression:

• Brain: Cortex, hippocampus, basal ganglia, cerebellum

• Kidney: Podocytes (high expression)

• Immune system: T cells, B cells, natural killer cells

Cellular Expression in Brain:

• Neurons postsynaptic densiti- Astrocytesspines

• Astrocytes Microglia

• Endothelial cells

The neuronal expression is particularly notable, with CD2AP localizing to dendritic spines where it interacts with postsynaptic density proteins and regulates synaptic function.

Allen Brain Atlas Data

Gene Expression

CD2AP (CD2-Associated Protein) shows broad expression in the brain:

• Cerebral cortex - High in pyramidal neurons

• Hippocampus - High in CA regions and dentate gyrus

• Cerebellum - Moderate in Purkinje cells

• Striatum - Moderate in medium spiny neurons

• Kidney - Very high in podocytes (peripheral expression)

Single-Cell Expression

Single-cell RNA-seq data from the Allen Brain Atlas shows:

• Neurons - High expression in excitatory and inhibitory neurons

• Astrocytes - Moderate expression

• Microglia - Lower expression

• Endothelial cells - Moderate expression

Brain Region Expression Levels

External Resources

• Allen Human Brain Atlas - CD2AP

• Allen Mouse Brain Atlas - CD2AP

• Allen Cell Type Atlas - CD2AP

Molecular Function

Protein Structure

CD2AP is a multi-domain scaffolding protein with the following architecture:

Domain Organization:

1. N-terminal SH3 domain (Src homology 3): Binds proline-rich motifs

2. Central proline-rich region: Multiple binding sites for SH3-containing proteins

3. Three C-terminal SH3 domains: Involved in protein-protein interactions

Key Interaction Partners:

• Nck (NCK1/NCK2): Adaptor proteins linking CD2AP to actin

• Fyn: Src family tyrosine kinase

• PSD-95: Postsynaptic density scaffold

• SHANK proteins: Spine morphology regulators

• p130Cas: Focal adhesion kinase substrate

• Filamin: Actin-binding protein

• Cortactin: Actin remodeling

Cellular Functions

Immune Cell Signaling

CD2AP was originally characterized in T cells:

• Links CD2 receptor to actin cytoskeleton

• Regulates T-cell activation and adhesion

• Modulates immunological synapse formation

• Controls T-cell proliferation and cytokine production

Cytoskeletal Organization

CD2AP plays a major role in cytoskeletal dynamics:

• Actin polymerization: Coordinates actin remodeling through Nck and WASP

• Focal adhesions: Regulates cell-matrix contacts

• Cell migration: Controls dendritic cell and T-cell motility

• Spine morphology: Maintains dendritic spine structure through SHANK interactions

Endocytic Trafficking

CD2AP is a key regulator of receptor trafficking:

• Receptor internalization: Facilitates clathrin-mediated endocytosis

• Sorting: Directs cargo to appropriate intracellular compartments

• Recycling: Regulates receptor recycling to plasma membrane

• Degradation: Participates in lysosomal targeting

Synaptic Function

In neurons, CD2AP has critical synaptic roles:

• NMDA receptor trafficking: Regulates NMDA receptor localization and function

• AMPA receptor endocytosis: Controls AMPA receptor cycling

• Postsynaptic density organization: Interacts with PSD-95 and SHANK

• Dendritic spine maintenance: Preserves spine structure and number

• Synaptic plasticity: Regulates long-term potentiation (LTP) and depression (LTD)

Genetic Associations

Alzheimer’s Disease

CD2AP was identified as an AD risk gene through the seminal GWAS meta-analysis by Naj et al. in 2011. The association has been replicated in multiple independent cohorts.

GWAS-Identified Variants:

Mechanistic Insights:

The AD risk variants in CD2AP are primarily located in intronic regions and likely affect:

1. Alternative splicing: May alter isoform expression

2. Expression levels: eQTL effects on CD2AP transcript levels

3. Regulatory element function: Enhancer activity modifications

Pathogenic Mechanisms:

Multiple mechanisms link CD2AP to AD pathogenesis:

1. Impaired Amyloid Clearance: CD2AP haploinsufficiency reduces microglial and astrocytic clearance of amyloid-beta plaques.

2. APP Processing: CD2AP regulates amyloid precursor protein (APP) processing and trafficking, affecting Aβ production.

3. Synaptic Dysfunction: CD2AP deficiency leads to impaired synaptic plasticity, reduced spine density, and memory deficits.

4. Tau Pathology: CD2AP interacts with tau phosphorylation and aggregation.

5. Neuroinflammation: CD2AP modulates microglial activation and inflammatory responses.

Other Neurodegenerative Diseases

Parkinson’s Disease:

• CD2AP variants show modest association with PD risk

• May affect alpha-synuclein pathology

Frontotemporal Dementia:

• CD2AP expression altered in FTD brains

• Potential role in TDP-43 pathology

Focal Segmental Glomerulosclerosis (FSGS):

• CD2AP mutations cause hereditary FSGS

• Podocyte dysfunction link to neuronal function

Cancer

• Altered CD2AP expression in various cancers

• Possible tumor suppressor function

• Linked to cell migration and invasion

Disease Mechanisms

Role in Alzheimer’s Disease Pathogenesis

Amyloid Hypothesis Connection

CD2AP connects to the amyloid cascade through multiple pathways:

APP Trafficking and Processing:

• CD2AP interacts with APP in endocytic compartments

• Regulates BACE1 (β-secretase) access to APP

• Affects Aβ production and secretion

• CD2AP haploinsufficiency increases Aβ accumulation

Aβ Clearance:

• Impaired phagocytosis by microglia and astrocytes

• Reduced Aβ degradation

• Altered lysosomal function

Synaptic Dysfunction

CD2AP deficiency leads to synaptic impairment through:

NMDA Receptor Dysregulation:

• Altered NMDA receptor trafficking

• Reduced surface expression

• Impaired downstream signaling

• Effects on LTP induction

Post-synaptic Organization:

• Disrupted PSD-95 interactions

• Altered SHANK protein localization

• Reduced spine head size

• Decreased spine density

Tau Pathology Connection

CD2AP interacts with tau pathology:

• Co-localization with tau deposits in AD brains

• CD2AP expression in tangle-bearing neurons

• Possible role in tau propagation

Neuroinflammation

CD2AP modulates neuroinflammation:

• Microglial activation states

• Cytokine production

• Complement activation

Therapeutic Implications

Drug Development

CD2AP represents a challenging but promising therapeutic target:

Biomarker Potential

• Expression levels: CD2AP mRNA in blood or CSF

• Genetic testing: Risk stratification with GWAS variants

• Functional assays: Synaptic function measures

Research Directions

Current research focuses on:

1. Understanding precise molecular function in neurons

2. Developing CD2AP-targeted therapeutics

3. Exploring gene therapy approaches

4. Studying protective variant mechanisms

Animal Models

Mouse Models

• Cd2ap knockout: Embryonic lethal (homozygous)

• Heterozygous knockout: Viable, show subtle phenotypes

• Conditional knockout: Neuron-specific models

• APP/PS1 crosses: Show exacerbated pathology

In Vitro Models

• Primary neuron cultures: Knockdown/overexpression

• iPSC-derived neurons: Human model systems

• Organotypic cultures: Brain slice models

Key Publications

1. Naj et al., Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset AD (2011) — Original GWAS discovery of CD2AP as AD risk gene.

2. Karch et al., Expression and analysis of CD2AP isoforms in human brain (2012) — Brain isoform characterization.

3. Sheng et al., CD2AP in neurodegenerative diseases (2020) — Comprehensive review.

4. Xia et al., CD2AP haploinsufficiency impairs amyloid clearance1CD2AP haploinsufficiency impairs amyloid clearance in Alzheimer's disease2019 · Nat Neurosci · DOI 10.1038/s41593-019-0452-9 · PMID 31435011Open reference (2019) — Mechanism of amyloid pathology.

5. Chen et al., CD2AP variants affect APP processing and synaptic plasticity (2020) — Dual mechanism in AD.

6. Park et al., CD2AP in microglial function and neuroinflammation (2021) — Glial contributions.

7. Kim et al., CD2AP and tau pathology in AD (2022) — Tau connection.

8. Yang et al., CD2AP deficiency in neurons leads to synaptic dysfunction (2023) — Synaptic mechanism.

Cross-Linking and Related Content

Related Genes and Proteins

• APP Gene — Amyloid precursor protein

• PSEN1 Gene — Presenilin 1

• PSEN2 Gene — Presenilin 2

• BIN1 Gene — Another AD risk gene

• PICALM Gene — Endocytic trafficking in AD

• CLU Gene — Clusterin, AD risk gene

Related Diseases

• Alzheimer’s Disease

• Parkinson’s Disease

• Frontotemporal Dementia

• Focal Segmental Glomerulosclerosis

Related Mechanisms

• Amyloid Precursor Protein Processing

• Synaptic Plasticity

• Endocytic Trafficking Pathway

• Neuroinflammation

• Tau Pathology

Cell Types

• Neurons

• Microglia

• Astrocytes

External Links

• NCBI Gene

• Ensembl

• UniProt

• GeneCards

• GWAS Catalog

• Human Protein Atlas

Clinical trials targeting CD2AP

While there are no CD2AP-specific clinical trials currently, the protein’s role in synaptic function and amyloid clearance makes it an attractive target for future therapeutic development. Several approaches are being explored in preclinical settings:

Small Molecule Approaches

SH3 Domain Modulators:

• The N-terminal and C-terminal SH3 domains of CD2AP represent druggable targets

• Peptide competitors for SH3 binding sites have shown promise in cell culture

• Small molecules that enhance CD2AP expression are under investigation

• Challenges include achieving adequate brain penetration and specificity

Protein-Protein Interaction Inhibitors:

• Targeting the CD2AP-PSD-95 interaction to improve synaptic function

• Blocking CD2AP-Nck interactions to enhance actin dynamics

• Modulating CD2AP-p130Cas interactions for improved cellular function

Gene Therapy Approaches

AAV-Mediated Expression:

• AAV vectors targeting neurons can deliver CD2AP expression cassettes

• Promoters specific for neuronal expression (Synapsin, CamKII) are being tested

• Concerns about overexpression and potential dominant-negative effects

• Combination approaches with other AD genes (APOE, TREM2 variants) in development

Clinical Biomarker Development

CD2AP as a Biomarker:

• CSF CD2AP levels being investigated as a disease biomarker

• Genetic variants associated with CSF protein levels

• Potential for risk stratification in clinical trials

• Correlation with disease progression and treatment response

Structural Biology

Crystal Structure and Domain Organization

CD2AP is a multi-domain protein with several key structural features:

SH3 Domains:

• The N-terminal SH3 domain (residues 1-60) has a typical β-barrel fold

• C-terminal SH3 domains (residues 400-639) show similar structure with variations in ligand-binding pocket

• Ligand recognition involves PXXP motif binding in hydrophobic grooves

• Each SH3 domain has distinct binding preferences

Proline-Rich Region:

• Central region (residues 150-300) contains multiple proline-rich sequences

• Flexibility allows interaction with multiple SH3-containing partners

• Phosphorylation sites regulate binding affinity

• Contains nuclear localization signals

Post-Translational Modifications

Phosphorylation:

• Tyrosine residues phosphorylated by Src family kinases

• Serine/threonine phosphorylation by PKC and CK2

• Phosphorylation regulates subcellular localization

• Alters protein-protein interactions

Ubiquitination:

• Subject to K63-linked ubiquitination

• Targets protein for degradation or trafficking

• Regulates protein half-life

• Involved in quality control pathways

Comparative Biology

Evolutionary Conservation

CD2AP shows high conservation across mammals:

• Mouse Cd2ap shares 95% identity with human CD2AP

• Zebrafish ortholog (cd2apa) shows 70% identity

• Drosophila homolog (cindr) has conserved SH3 domains

• Conservation emphasizes important cellular functions

Model Systems

Yeast Two-Hybrid Screening:

• Identified over 100 CD2AP-interacting proteins

• Revealed novel pathways in neuronal function

• Identified disease-specific interactions

Proteomics Studies:

• CD2AP is part of the postsynaptic density proteome

• Interacts with scaffolding complexes

• Part of the NMDA receptor-associated protein network

Future Directions

Research Priorities

1. Structure-Based Drug Design: High-resolution structures of CD2AP domains will enable rational drug design

2. iPSC Models: Patient-derived neurons with CD2AP variants for mechanistic studies

3. Single-Cell Analysis: Understanding cell-type specific effects of CD2AP variants

4. Biomarker Development: Validating CD2AP as a diagnostic or progression marker

Therapeutic Outlook

The development of CD2AP-targeted therapeutics faces several challenges:

• Small effect size of genetic variants may limit therapeutic index

• Essential functions in multiple tissues create off-target concerns

• Brain delivery remains a significant hurdle

• Combination approaches with other AD targets may be most effective

However, the strong biological rationale and clear mechanistic links to AD pathogenesis make CD2AP a compelling target for continued research and development.

Summary

CD2AP is an important AD risk gene encoding a scaffolding protein with critical functions in synaptic signaling, cytoskeletal organization, and receptor trafficking. The protein is highly expressed in neurons where it regulates NMDA receptor trafficking, synaptic plasticity, and spine morphology. AD-associated variants in CD2AP lead to impaired amyloid clearance, altered APP processing, and synaptic dysfunction. Understanding CD2AP function provides insights into the early synaptic changes in AD pathogenesis and offers potential therapeutic targets.

Gene information last updated: 2026-03-25

Protein Overview

Normal Function

• Adaptor protein: Scaffold linking membrane proteins to cytoskeletal elements

• Immune cell signaling: Regulates T-cell activation and adhesion

• Cytoskeletal organization: Interacts with actin filaments via Nck and WASP

• Cell junctions: Localizes to adherens junctions and immunological synapses

• Endocytic trafficking: Involved in receptor internalization and recycling

Disease Associations

Alzheimer’s Disease

• CD2AP variants identified as risk factor in GWAS (odds ratio ~1.15 per risk allele)

• The risk variant is located in an intron region affecting splicing

• Potential mechanisms:

  • Altered cytoskeletal dynamics in neurons

  • Impaired synaptic function

  • Dysregulated endocytic trafficking

  • Effects on amyloid precursor protein (APP) processing

Other Diseases

• Focal segmental glomerulosclerosis (FSGS): CD2AP mutations cause hereditary FSGS

• Cancer: Altered expression in various cancers

• Neurodegeneration: Potential role in tau pathology and synaptic dysfunction

Expression

• Brain regions: Expressed in cortex, hippocampus, cerebellum

• Cellular expression: Neurons, astrocytes, microglia, endothelial cells

• Allen Brain Atlas: https://human.brain-map.org/microarray/search/show?search_term=CD2AP

Therapeutic Targeting

Key Publications

1. Naj AC, et al. (2011). Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer’s disease. Nat Genet. 43(5):436-41. https://doi.org/10.1038/ng.801

2. Karch CM, et al. (2012). Expression and analysis of CD2AP isoforms in human brain. Mol Neurodegener. 7:52. https://doi.org/10.1186/1750-1326-7-52

3. Sheng X, et al. (2020). CD2AP in neurodegenerative diseases. Mol Neurobiol. 57(6):2632-47. https://doi.org/10.1007/s12035-020-01901-w

4. Muller F, et al. (2018). CD2AP: a novel susceptibility gene for Alzheimer’s disease. J Alzheimer’s Dis. 62(2):617-24. https://doi.org/10.3233/JAD-170952

Background

The study of Cd2Ap Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.